Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.
Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer
Professor of Medicine and Winterhof Family Professor of Breast Oncology
University of California San Francisco Comprehensive Cancer Center
San Francisco, CA
University of California San Francisco Comprehensive Cancer Center
San Francisco, CA
Related Items
JHOP - June 2024 Vol 14, No 3 published on May 23, 2024 in Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Breast Cancer, CDK4/6 Inhibitors, Adverse Events